𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Mutation Detection in KRAS Exon 1 by Constant Denaturant Capillary Electrophoresis in 96 Parallel Capillaries

✍ Scribed by Jens Bjørheim; Marek Minarik; Gustav Gaudernack; Per Olaf Ekstrøm


Publisher
Elsevier Science
Year
2002
Tongue
English
Weight
74 KB
Volume
304
Category
Article
ISSN
0003-2697

No coin nor oath required. For personal study only.

✦ Synopsis


Mutations in KRAS exon 1 oncogene are frequently found in colon carcinomas. A correlation between the mutated KRAS and the prognosis and outcome of treatment of colon cancer patients was reported in the literature. The object of our work was to establish a high-throughput method with high sensitivity to enable screening of tumor mutation status of KRAS exon 1 in large groups of colon cancer patients. KRAS exon 1 sequences from DNA isolated from 191 sporadic colon cancers were PCR amplified using one primer labeled with fluorescein and a second primer extended by a GC-clamp. After PCR amplification samples were subjected to automated 96-array constant denaturant capillary electrophoresis using a modified MegaBACE 1000 sequencing instrument. Mutant samples were identified by characteristic peak patterns. The sensitivity of detection of a mutant allele in a background of the wild-type alleles was 0.3%. Using the 96-array instrument a typical screening of 191 samples for KRAS mutation status could be performed within 2 h. A KRAS exon 1 mutation was found in 66 of 191 (34.6%) of the samples. The 96-array constant denaturant capillary electrophoresis provides an opportunity for the high-sensitivity screening of large cancer populations for KRAS exon 1 mutations.


📜 SIMILAR VOLUMES


Denaturing capillary electrophoresis for
✍ Lucie Benesova; Milos Pesek; Barbora Belsanova; Patrik Sekerka; Marek Minarik 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 249 KB

## Abstract The presence of activating mutations within the tyrosine kinase domain of the epidermal growth factor receptor gene has been attributed to a positive response to biological therapy of lung cancer by small‐molecular tyrosine kinase inhibitors, gefitinib and erlotinib. Among the two most